Ligand-dependent activation of EGFR in follicular dendritic cells sarcoma is sustained by local production of cognate ligands

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5027-5038

  Vermi, William ^a,g   Giurisato, Emanuele ^b   Lonardi, Silvia ^a   Balzarini, Piera ^a   Rossi, Elisa ^b   Medicina, Daniela ^a   Bosisio, Daniela ^a   Sozzani, Silvano ^a,h   Pellegrini, Wilma ^a   Doglioni, Claudio ^c   Marchetti, Antonio ^d   Rossi, Giulio ^e   Pileri, Stefano ^f   Facchetti, Fabio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETACELLULIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; STAT PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; UO 126;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; FOLLICULAR DENDRITIC CELL SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BUTADIENES; CELL CYCLE; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 7; DENDRITIC CELLS, FOLLICULAR; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LIGANDS; NITRILES; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84884558345     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1275     Document Type: Article

References (50)

1. Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41-8.
2. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117-34.
3. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994;91:7727-31.
4. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
5. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
6. Pines G, Kostler WJ, Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 2010;584:2699-706.
7. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007;117:2051-8.
8. Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 2012;18:432-41.
9. Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, et al. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. J Cell Physiol 2008;217:409-22.
10. Vermi W, Lonardi S, Bosisio D, Uguccioni M, Danelon G, Pileri S, et al. Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol 2008;216:356-64.
11. Sun X, Chang KC, Abruzzo LV, Lai R, Younes A, Jones D. Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease. Hum Pathol 2003;34:835-40.
12. Krautler NJ, Kana V, Kranich J, Tian Y, Perera D, Lemm D, et al. Follicular dendritic cells emerge from ubiquitous perivascular precursors. Cell 2012;150:194-206.
13. van Nierop K, de Groot C. Human follicular dendritic cells: function, origin and development. Semin Immunol 2002;14:251-7.
14. Aguzzi A, Krautler NJ. Characterizing follicular dendritic cells: a progress report. Eur J Immunol 2010;40:2134-8.
15. Chan JK, Fletcher CD, Nayler SJ, Cooper K. Follicular dendritic cell sarcoma. Clinicopathologic analysis of 17 cases suggesting amalignant potential higher than currently recognized. Cancer 1997;79:294-313.
16. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, et al. Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol 2007;82:725-8.
17. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumors of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002;41:1-29.
18. Vermi W, Lonardi S, Morassi M, Rossini C, Tardanico R, Venturini M, et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology 2009;214:877-86.
19. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
20. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008;68:1953-61.
21. Turri-Zanoni M, Medicina D, Lombardi D, Ungari M, Balzarini P, Rossini C, et al. Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases. Head Neck 2012;35:1066-77.
22. Grogg KL, Lae ME, Kurtin PJ, Macon WR. Clusterin expression distinguishes follicular dendritic cell tumors from other dendritic cell neoplasms: report of a novel follicular dendritic cell marker and clinicopathologic data on 12 additional follicular dendritic cell tumors and 6 additional interdigitating dendritic cell tumors. Am J Surg Pathol 2004;28:988-98.
23. Chan JKC. Proliferative lesions of follicular dendritic cells: an overview, including a detailed account of follicular dendritic cell sarcoma, a neoplasm with many faces and uncommon etiologic associations. Adv Anat Pathol 1997;4:387-411.
24. Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, Hagemeijer A, Sciot R. Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. Am J Surg Pathol 2002;26:662-9.
25. Pauwels P, Dal Cin P, Vlasveld LT, Aleva RM, van Erp WF, Jones D. A chromosomal abnormality in hyaline vascular Castleman's disease: evidence for clonal proliferation of dysplastic stromal cells. Am J Surg Pathol 2000;24:882-8.
26. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol 1988;5:346-64.
27. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507.
28. Sander B, Middel P, Gunawan B, Schulten HJ, Baum F, Golas MM, et al. Follicular dendritic cell sarcoma of the spleen. Hum Pathol 2007;38:668-72.
29. Della Porta M, Rigolin GM, Bugli AM, Bardi A, Bragotti LZ, Bigoni R, et al. Differentiation of follicular dendritic sarcoma cells into functional myeloid-dendritic cell-like elements. Eur J Haematol 2003;70:315-8.
30. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-43.
31. Dunbar AJ, Goddard C. Structure-function and biological role of Betacellulin. Int J Biochem Cell Biol 2000;32:805-15.
32. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, et al. Betacellulin: a mitogen from pancreatic beta cell tumors. Science 1993;259:1604-7.
33. Miyagawa J, Hanafusa O, Sasada R, Yamamoto K, Igarashi K, Yamamori K, et al. Immunohistochemical localization of Betacellulin, a new member of the EGF family, in normal human pancreas and islet tumor cells. Endocr J 1999;46:755-64.
34. Burns JA, Li Y, Cheney CA, Ou Y, Franlin-Pfeifer LL, Kuklin N, et al. Choice of fixative is crucial to successful immunohistochemical detection of phosphoproteins in paraffin-embedded tumor tissues. J Histochem Cytochem 2009;57:257-64.
35. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005;11:4338-40.
36. Mueller C, Edmiston KH, Carpenter C, Gaffney E, Ryan C, Ward R, et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 2011;6:e23780.
37. Kersting C, Packeisen J, Leidinger B, Brandt B, von Wasielewski R, Winkelmann W, et al. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol 2006;59:585-90.
38. Seno M, Tada H, Kosaka M, Sasada R, Igarashi K, Shing Y, et al. Human Betacellulin, a member of the EGF family dominantly expressed in pancreas and small intestine, is fully active in a monomeric form. Growth Factors 1996;13:181-91.
39. Sasada R, Ono Y, Taniyama Y, Shing Y, Folkman J, Igarashi K. Cloning and expression of cDNA encoding human Betacellulin, a new member of the EGF family. Biochem Biophys Res Commun 1993;190:1173-9.
40. Oh YS, Shin S, Lee YJ, Kim EH, Jun. HS. Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors. PLoS One 2011;6:e23894.
41. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
42. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
43. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
44. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
45. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10.
46. Ha HT, Griffith KA, Zalupski MM, Schuetze SM, Thomas DG, Lucas DR, et al. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma. Am J Clin Oncol 2012;36:77-82.
47. Hawkes E, Cunningham D. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. J Clin Oncol 2010;28:e529-31; author reply e32-e33.
48. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapyrefractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
49. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
50. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.